HomeCLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Lipogems® Announces 140 Independent Peer Reviewed Publications with 5 Years of Follow up in Orthopaedics

Lipogems

Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems’ MicroFat with 5 years of follow up in orthopaedics.

“Lipogems has sought out to help patients that have tried conservative options and other therapies with limited relief. As a science driven company, we are proud to see that 98% of the 140 peer-reviewed publications that studied the Lipogems device and tissue are independent studies from well-respected academic, military, and private practice institutions,” said Giorgio Ninzoli, President of Lipogems International. “The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat.”

Lipogems has been used in more than 60,000 procedures worldwide and is currently FDA cleared for use in the US for general applications in orthopaedics, arthroscopy, and nine other specialties since 2014. Lipogems partners with leading institutions to keep their patients in their care continuum, offering physicians a compliant option for both surgical and non-operative applications.

“Many physicians have patients that have exhausted other therapies and they don’t have many options to help them. We are grateful for these researchers seeing benefit in the previous evidence that has shown the power of the Lipogems MicroFat and that they have taken on the task to independently advance evidence-based medicine which benefits patients in orthopaedics, colorectal surgery, and general surgery,” Said Carl Llewellyn, President, Lipogems USA.

SourceLipogems
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society 2023 Annual Meeting

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."

Research Team at UNC Validates PixCell Medical’s HemoScreen as Game-Changer for Clozapine Monitoring in Psychiatry

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).

Medical Device News Magazine

Editorial Contact: mdnewsmagazine@infomeddnews.com

Medical Device News Magazine can help promote your medical devices, technologies, products or services. Advertising Contact: advmdn@infomeddnews.com

Telephone

© Copyright 2022 Medical Device News Magazine, is a division of PTM Healthcare Marketing, Inc

By using this website you agree to accept Medical Device News Magazine Privacy Policy